Literature DB >> 7561138

Antibodies to lipopolysaccharide.

I R Poxton1.   

Abstract

Lipopolysaccharides (LPS) are indispensable structural components of the Gram-negative bacterial outer membrane and are major determinants of virulence in pathogenic species. In the infected host LPS is better known as endotoxin where it acts as a potent stimulator of the inflammatory response. This article reviews the methods for the production and measurement of anti-LPS antibodies, and then describes the uses to which these methods have been employed. Antibodies to LPS (either monoclonal or polyclonal) may be used directly as immunotherapeutic agents for the treatment of Gram-negative sepsis or endotoxaemia, or as probes for the diagnosis and epidemiological investigation of Gram-negative bacterial infections. Antibodies are useful tools for investigation of the chemical structure of LPS, its expression on bacteria and to study the role of LPS in pathogenic mechanisms. The detection and quantitation of anti-LPS antibodies has formed the basis of classical and more recent serological studies of major bacterial infections.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561138     DOI: 10.1016/0022-1759(95)00123-r

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  14 in total

1.  Antibody response to lipopolysaccharide in patients colonized or infected with an endemic strain of Acinetobacter genomic species 13 sensu Tjernberg and Ursing.

Authors:  R Pantophlet; H Seifert; L Brade; H Brade
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

Review 2.  The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin.

Authors:  Lara Marks
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

3.  Shift of C3 deposition from localization in the glomerulus into the tubulo-interstitial compartment in the absence of secreted IgM in immune complex glomerulonephritis.

Authors:  C Vaculik; B M Rüger; G Yanagida; D Hollemann; A Soleiman; U M Losert; J Chen; M B Fischer
Journal:  Clin Exp Immunol       Date:  2007-11-07       Impact factor: 4.330

4.  Prenatal androgen exposure modulates cellular and humoral immune function of black-headed gull chicks.

Authors:  Wendt Müller; Ton G G Groothuis; Alice Kasprzik; Cor Dijkstra; Rauno V Alatalo; Heli Siitari
Journal:  Proc Biol Sci       Date:  2005-09-22       Impact factor: 5.349

5.  Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine.

Authors:  E Bennett-Guerrero; T J McIntosh; G R Barclay; D S Snyder; R J Gibbs; M G Mythen; I R Poxton
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

6.  Studies on the reductive amination of 3-deoxy-D-manno-octulosonic acid (Kdo).

Authors:  H D Grimmecke; H Brade
Journal:  Glycoconj J       Date:  1998-06       Impact factor: 2.916

7.  Pathogen specific carbohydrate antigen microarrays: a chip for detection of Salmonella O-antigen specific antibodies.

Authors:  Ola Blixt; Julia Hoffmann; Stefan Svenson; Thomas Norberg
Journal:  Glycoconj J       Date:  2007-06-09       Impact factor: 2.916

8.  Characterization of a neutralizing monoclonal antibody directed at the lipopolysaccharide of Chlamydia pneumoniae.

Authors:  E M Peterson; L M de la Maza; L Brade; H Brade
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

Review 9.  Regulation of Aicda expression and AID activity.

Authors:  Hong Zan; Paolo Casali
Journal:  Autoimmunity       Date:  2013-01-17       Impact factor: 2.815

10.  Potent Killing of Pseudomonas aeruginosa by an Antibody-Antibiotic Conjugate.

Authors:  Kimberly K Kajihara; Homer Pantua; Hilda Hernandez-Barry; Meredith Hazen; Kiran Deshmukh; Nancy Chiang; Rachana Ohri; Erick R Castellanos; Lynn Martin; Marissa L Matsumoto; Jian Payandeh; Kelly M Storek; Kellen Schneider; Peter A Smith; Michael F T Koehler; Siao Ping Tsai; Richard Vandlen; Kelly M Loyet; Gerald Nakamura; Thomas Pillow; Dhaya Seshasayee; Sharookh B Kapadia; Wouter L W Hazenbos
Journal:  mBio       Date:  2021-06-01       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.